Immuno-oncology
Conference Coverage
Diet appears to play an important role in response to anti-PD-1 cancer immunotherapy
Diet appears to affect response to anti-PD-1 cancer immunotherapy, likely by its effect on the gut microbiome.
Conference Coverage
First-line avelumab/axitinib for RCC benefits wide range of patients
SAN FRANCISCO – Subgroup analyses of the JAVELIN Renal 101 trial show that first-line avelumab/axitinib yields better PFS and ORRs than sunitinib...
Article
The Use of Immuno-Oncology Treatments in the VA
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma
The 3-year overall survival rate for patients treated with nivolumab was 51.2%, compared with 21.6% for those who received dacarbazine.
Conference Coverage
Checkpoint inhibitor seems safe and effective for patients with HIV
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...
Conference Coverage
Researchers consider R/R ALL drugs in the first-line setting
CHICAGO –
Latest News
Researchers share Nobel Prize for cancer immunotherapy discoveries
Dr. James P. Allison and Dr. Tasuku Honjo share the Nobel Prize for their work on preventing brakes on T cells, which led to the development of...
News
Nivolumab plus ipilimumab effective in melanoma brain metastases
Treatment with nivolumab plus ipilimumab resulted in clinically meaningful efficacy for melanoma patients with asymptomatic, previously untreated...